AUPH
Aurinia Pharmaceuticals Inc. Health Care Pharmaceutical Preparations Russell 3000
$16.65Close
$2.2BMarket cap
$12.12 – $18.6252-week range
Nov 3, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
Cautions
- Distribution down-day volume 1.6× up-day volume over 50 sessions
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
11%
1wk
down 1.2%
price change
1mo
up 2.8%
price change
12-month return
up 37%
market up 11% ·
its own up 25%
F-score
8 / 9
Exceptional
Altman Z
8.03
Low risk
P/E
7.7×
price / earnings
PEG
0.00
P/E / EPS growth
P/B
3.8×
price / book
Earnings yield
up 4.9%
EBIT / enterprise value
Cheaper than
62%
of the market · cheap
Revenue growth
up 20%
year on year
EPS growth
up 1%
latest quarter · -78 pts
Sales growth
up 14%
latest quarter · -5 pts
ROE
up 60%
return on equity
Free cash margin
up 48%
$135.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-0.6×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- profits not fully backed by cash
- profitable on its assets
- generating cash from operations
- profitability improving
- reduced long-term debt
- short-term liquidity improved
- no new shares issued
- gross margin widened
- assets working harder
Trade setup
ATR%
2.8%
$0.47 a day · 2×ATR $15.72
RS
74 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.1×
vs 50-day average
Up/down volume
0.63
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Profit not backed by cash Reported profit of $287.2M came with $135.7M of operating cash flow. Profit that cash does not follow is the classic signature of aggressive accounting.
Last reported
Oct 30, 2026
Results reaction
Oct 30, 2026-1% vs market2 sessions after results
Financials
- Gross 88%
- Net 101%
- Free cash 48%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $50.1M | $45.6M | $134.0M | $175.5M | $235.1M | $283.1M |
| Gross margin | 100% | 98% | 96% | 92% | 88% | 88% |
| Operating income | -$104.3M | -$180.7M | -$111.5M | -$91.7M | -$4.7M | $104.9M |
| Net income | -$102.7M | -$181.0M | -$108.2M | -$78.0M | $5.8M | $287.2M |
| Net margin | -205% | -397% | -81% | -44% | 2% | 101% |
| Earnings per share | -$0.87 | -$1.40 | -$0.76 | -$0.54 | $0.04 | $2.07 |
| Free cash flow | -$69.9M | -$157.7M | -$79.5M | -$33.5M | $44.4M | $135.7M |
| Free cash margin | -139% | -346% | -59% | -19% | 19% | 48% |
| Cash | $272.4M | $231.6M | $94.1M | $48.8M | $83.4M | $80.2M |
| Shareholders' equity | $407.8M | $479.1M | $405.4M | $378.0M | $377.5M | $581.3M |
| Shares outstanding | 126.70m | 141.60m | 142.27m | 143.83m | 140.88m | 132.32m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 30, 2026 | Quarterly ↗ | Sep 30, 2026 | 30d |
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Jul 31, 2025 | Quarterly ↗ | Jun 30, 2025 | 31d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 15, 2024 | Annual ↗ | Dec 31, 2023 | 46d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 30, 2026 | Results ↗ |
| Aug 19, 2026 | Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| Jun 4, 2026 | Shareholder vote ↗ |
| May 11, 2026 | Acquisition or disposal ↗ |
| May 7, 2026 | Results ↗ |
| Apr 3, 2026 | Material agreement · Regulation FD ↗ |
| Mar 23, 2026 | Director or officer change ↗ |
| Feb 26, 2026 | Results ↗ |
| Nov 4, 2025 | Results ↗ |
| Jul 31, 2025 | Results · Other events ↗ |
| Jun 30, 2025 | Other events ↗ |